Introduction
============

Coagulase-negative staphylococci (CNS) rank among opportunistic pathogens being a frequent etiologic agent of nosocomial infections connected with the presence of medical devices. The cause for this should be sought in the ability of CNS to create biofilm whereby they pose a particular threat for people with valve prostheses and the ones with implants or catheters \[[@B1]\]. A group which is particularly susceptible to hospital infections are very low birth weight (VLBW) neonates in which CNS are identified as 48 up to 80% of all etiologic agents causing late-onset diseases (LOD). The most frequently isolated species are *Staphylococcus epidermidis* (58% -- 76%) and then *Staphylococcus haemolyticus* (14% -- 32%) \[[@B2]-[@B4]\].

Medicating infections in neonates poses a big problem as there is the need to use a therapy quickly. In the event of infections caused by hospital pathogens, the empirical treatment is adjusted based on information on drug-resistance of the bacteria persisting in the ward. A high percentage of *S. epidermidis* and *S. haemolyticus* isolates coming from neonates are resistant to many antibiotics: methicillin (86% -- 100%), gentamicin (80% -- 100%), erythromycin (65% -- 100%), oxacillin (92% -- 100%), or clindamycin (80% -- 100%) \[[@B5]-[@B7]\].

The growing importance of coagulase-negative staphylococci, including multidrug-resistant strains, among other etiologic agents of nosocomial infections, forcing researchers to look for the most effective ways to combat these pathogens. Therefore, the aim of the project was to analyze the prevalence of antibiotic resistance in invasive coagulase-negative staphylococci isolates derived from very low birth weight neonates hospitalized in two Polish Neonatal Intensive Care Units (NICUs).

Methods
=======

Continuous prospective target surveillance of infections was conducted from 1.01.2009 to 31.12.2009 at two Polish NICUs that participated in the Polish Neonatology Surveillance Network (PNSN). The surveillance concerned infants hospitalized at cooperating units whose birth weight was ≤1500 grams (from birth to discharge, or until the weight of 1800 grams or death). All cases of infections were subject to registration, regardless of the time of occurrence of the first symptoms as early-onset infection (EOI) or late-onset infection (LOI). Case patients were defined according to Gastmeier et al. \[[@B8]\] with modifications as neonates with very low birth weight (VLBW) when they had clinical signs of septicemia or of pneumonia, as previously described \[[@B9]\]. The study covered 386 VLBW neonates, among which 262 cases of LOI infection were detected with predominance of CNS (123; 47%) including blood stream infections (54 cases, 43.9%), pneumonia (58 cases, 47.2%) and others.

(11 cases, 8.9%). Altogether, one hundred invasive coagulase-negative staphylococci isolates were collected and stored at the temperature of -80°C. Preliminary identification of species was performed using API Staph (bioMerieux) and than multiplex PCR method according to Pereira et al. \[[@B10]\].

Antibiotic susceptibility testing
---------------------------------

To determine the drug-resistance phenotype, the Kirby-Bauer disk diffusion method was used in which Müller-Hinton 2 LAB-AGAR™ (Biocorp) and antibiotic disks (Oxoid) were utilized: cefoxitin 30 μg, clindamycin 2 μg, erythromycin 15 μg, tigecycline 15 μg, ofloxacin 5 μg, gentamicin 10 μg, amikacin 30 μg, linezolid 10 μg and the E-test method enabling determination of MIC (Minimal Inhibitory Concentration) for teicoplanin and vancomycin (bioMerieux). The results were interpreted according to EUCAST (The European Committee on Antimicrobial Susceptibility Testing) 2012 \[[@B10]\].

Polymerase chain reaction, PCR
------------------------------

To isolate DNA, the Genomic Mini Set (A&A Biotechnology) was used according to the manufacturer's protocol. The presence of species-specific genes to *S. haemolyticus* or *S. epidermidis* and methicillin-resistance *mec*A gene was confirmed using multiplex PCR amplification according to Pereira et al. \[[@B11]\] with specific primers (Genomed). To detect genes coding the erythromycin-resistance, the multiplex PCR reaction was conducted on *ermA, ermC, msrA* genes and PCR on the *ermB* gene, according to the procedure described by Zmantar et al. \[[@B12]\]. The determination of *aac(6′)/aph(2″*), *aph(3′)-IIIa* and *ant(4′)-Ia* genes coding the aminoglycoside-resistance was conducted according to the procedure by Choi et al. \[[@B13]\]. The final pictures from electrophoresis were processed using QuantityOne software, as well as GelDoc2000 device (Bio-Rad, USA).

Results
=======

The species identification with the multiplex PCR indicated that 63% of the tested CNS isolates belonged to *S. epidermidis* species, while 28% to *S. haemolyticus* (Figure [1](#F1){ref-type="fig"})*.* The remaining 9% (n = 9) of isolates belonged to other CNS species, including 4% (n = 4) *S. warneri*, 2% (n = 2) *S. hominis*, 2% (n = 2) *S. xylosus* and 1% (n = 1) *S. capitis.*

![**An example of the outcome of the multiplex PCR reaction for determining the species of*Staphylococcus aureus*(108 bp),*Staphylococcus epidermidis*(124 bp),*Staphylococcus haemolyticus*(271 bp) and for detecting the presence of*mecA*gene (154 bp).** Legend: Lanes 1 -- 10 studied samples; 11 -- positive control reference *S. aureus* ATCC 33592; 2 -- positive control reference *S. epidermidis* ATCC 700296; 13 -- positive control reference *S. haemolyticus* ATCC 29970, 14 -- negative control; 15 -- marker (Eurx Perfect TM 100 bp DNA Ladder).](1476-0711-12-41-1){#F1}

A detailed analysis of drug resistance with the use of phenotypic and genotypic methods was carried out for isolates of the species *S. epidermidis* (n = 63) and *S. haemolyticus* (n = 28). Among the isolates tested, there was a very high percentage of multi-drug resistant strains. Among *S. epidermidis*, 98% (n = 62) of isolates were resistant to methicillin, 90% (n = 57) to erythromycin, 39% (n = 25) to clindamycin, 95% (n = 60) to gentamicin, 60% (n = 38) to amikacin, 36% (n = 23) to ofloxacin, 2% (n = 1) to tigecycline, 3% (n = 2) to linezolid and 13% (n = 8) to teicoplanin. Among *S. haemolyticus* isolates, 100% (n = 28) were resistant to methicillin, erythromycin and gentamicin, 18% (n = 5) to clindamycin, 50% (n = 14) to amikacin, 86% (n = 24) to ofloxacin, 14% (n = 4) to tigecycline and 4% (n = 1) to teicoplanin. No resistance to linezolid was detected for *S. haemolyticus* isolates. Moreover, all isolates of *S. epidermidis* and *S. haemolyticus* were susceptible to vancomycin (Figure [2](#F2){ref-type="fig"}).

![**The percentage of isolates of the species*S. epidermidis*and S*. haemolyticus*, resistant to the studied antibiotics.**](1476-0711-12-41-2){#F2}

Using E-test, the values for MIC~50~ and MIC~90~ were determined for teicoplanin and vancomycin. For *S. epidermidis*, MIC~50~ and MIC~90~ for teicoplanin was equal to 2 and 6, respectively, while for vancomycin, it was 2 and 3. For *S. haemolyticus*, MIC~50~ and MIC~90~ for teicoplanin was equal to 2 and 3, respectively, and for vancomycin, it was 2 and 3.

Among *S. epidermidis* isolates resistant to macrolides (n = 57), the cMLS~B~ and MS~B~ phenotypes were most common, and performed in 43% (n = 25) and 40% (n = 23) of isolates, respectively. While the iMLS~B~ phenotype was present in 16% (n = 9) of *S. epidermidis*. The MS~B~ phenotype was predominant among *S. haemolyticus* \`isolates (n = 28), and appeared in 82% of isolates (n = 23), whereas cMLS~B~ phenotype was detected in 18% of the isolates (n = 5). In the case of *S. heamolyticus*, the MS~B~ phenotype was not detected (Figure [3](#F3){ref-type="fig"}).

![**The percentage of isolates of the species*S. epidermidis*and S*. haemolyticus*with macrolide resistance phenotype cMLS**~**B**~**, iMLS**~**B**~**and MS**~**B**~**.**](1476-0711-12-41-3){#F3}

The presence of *mecA* gene was confirmed with the multiplex PCR method in 62 *S. epidermidis* (98%) isolates and in 28 isolates of the species *S. haemolyticus* (100%) (Figure [1](#F1){ref-type="fig"}).

The *ermC* gene was predominant in *S. epidermidis* isolates (n = 34; 60%), while in *S. haemolyticus* was present only in 2 isolates (7%)*.* On the other hand, *msrA* gene was prevalent in *S. haemolyticu*s isolates (n = 26; 93%), while in *S. epidermidis* it was much less frequent (n = 23; 40%). It is noteworthy to remark that one of the *S. haemolyticus* isolates possessed both *msrA* and *ermC* genes simultaneously. The presence of *ermA* oraz *ermB* genes was not demonstrated in the studied isolate pool (Figure [4](#F4){ref-type="fig"}).

![**An example of the outcome of the multiplex PCR reaction for determining the genes coding macrolide resistance*ermA*(139 bp),*ermC*(190 bp) and*msrA*(163 bp).** Legend: Lane 1 --marker (Eurx Perfect TM 100 bp DNA Ladder ); 2 -- 17 studied samples; 18 -- positive control reference *msrA* W2/28; 19 -- positive control reference *ermC* W2/55; 20 -- negative control.](1476-0711-12-41-4){#F4}

*S. epidermidis* isolates resistant to macrolides, of cMLS~B~ and iMLS~B~ resistance phenotype, possessed *ermC* gene (n = 34; 60%). While five *S. haemolyticus* isolates of cMLSB resistance phenotype demonstarted the presence of various genes, including three with *msrA* gene, in the second one *ermC* and in the remaining one of *ermC* and *msrA* genes at the same time. In all *S. epidermidis* isolates (n = 23; 100%) and *S. haemoltyticus* (n = 23; 100%) of MS~B~ phenotype, gene *msrA* was present.

Among the genes coding aminoglycoside resistance, *aac(6′)/aph(2″)* gene was the most frequent, and the genes more rare were *aph(3′)-Ia* and *aph(3′)-IIIa*. In *S. epidermidis*, isolates with the *aac(6′)/aph(2″)* gene were prevalent (n = 49; 83%), while in *S. haemolyticus*, the *aac(6′)/aph(2″)* was the most frequent together with *aph(3′)-IIIa* (n = 22; 84%) (Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}).

![**An example of the outcome of the multiplex PCR reaction for determining the genes coding aminoglycoside resistance*aac(6′)/aph(2″)*(491 bp),*aph(3′)-IIIa*(292 bp),*ant(4′)-Ia*(135 bp).** Legend: lanes 1 -- 16 studied samples; 17 -- positive control reference *aac(6\')/aph(2\")* and *aph(3\')-IIIa* W2/60; 18 -- positive control reference *aac(6\')/aph(2\")* and *ant(4\')-Ia* W2/9, 19 -- negative control, 20 -- marker (Eurx Perfect TM 100 bp DNA Ladder).](1476-0711-12-41-5){#F5}

![**Percentage of aminoglycoside resistance genes:*aac(6′)/aph(2″), aph(3′)-IIIa, ant(4′)-Ia*in isolates of the species*S. epidermidis*and*S. haemolyticus.***](1476-0711-12-41-6){#F6}

Discussion
==========

Infections caused by coagulase-negative staphylococci are among the most common causes of death among infants with very low birth weight \[[@B14]\]. This is due to the fact that staphylococcal biofilm can be formed on biomaterials, from which are made various types of devices used in patients chronically hospitalized. Bacteria growing in biofilm are characterized by an increased resistance to the host immune system and antibiotic use, making it more difficult and significantly extending the patient's hospitalization \[[@B1],[@B15]\].

The researched CNS isolates demonstrated multi-drug resistance. The studied *S. epidermidis* isolates and *S. haemolyticus* were resistant to methicillin, in 98% and 100%, respectively, as well as to the majority of the remaining antibiotics that were studied. These results are concurrent with the literature data where for CNS isolated from neonatal infections the percentage of methicillin-resistant strains (methicillin-resistant coagulase-negative staphylococci, MRCNS) was in the range of 86-100%, and, moreover, these bacteria was connected with multiple resistance to other antibiotics \[[@B6],[@B7]\].

Investigation of the *mecA* gene in CNS using the PCR technique is nowadays regarded as the gold standard with a view to determining methicillin resistance \[[@B11]\]. In our study, meticillin-resistance phenotype for all the researched strains was confirmed by the detection of the *mecA* gene. Similar results were described by other authors \[[@B11]\].

The group of isolates was characterized by high erythromycin resistance which was 84% for isolates of *S. epidermidis* and 100% for *S. haemolyticus*. The results obtained are similar to those of Bialkowska-Hobrzanska et al. where 100% of isolates *S. epidermidis* and 92% of *S. haemolyticus* isolated from neonates were erythromycin-resistant \[[@B16]\], as well as similar to the data obtained by Abd El Hafez et al. where the erythromycin resistance for isolates of *S. epidermidis* coming from neonates was 86% \[[@B6]\].

Clindamycin resistance was demonstrated in 26% of isolates of *S. epidermidis* and 28% of isolates of *S. haemolyticus*. The determined percentage of clindamycin resistance was significantly lower than that described by Bialkowska-Hobrzanska et al. where for *S. epidermidis* it was equal to 92%, and for *S. haemolyticus* 85% \[[@B16]\]; similarly, Abd El Hafez et al. demonstated 75.9% of isolates of *S. epidermidis* as resistant \[[@B6]\], and higher than that proven by van den Hoogen et al. equal to 15% for CNS altogether \[[@B17]\].

Among the *S. epidermidis* strains that were macrolide-resistant, the cMLS~B~ phenotype constituted 43% and MS~B~ 40% whereas in *S. haemolyticus* the most frequently detected MS~B~ phenotype occurred in 82% of isolates. Similar results were described by Gheradi et al. who researched CNS coming from hospital infections where 38% of isolates of *S. epidermidis* and 80% of isolates of *S. haemolyticus* had the MS~B~ phenotype and 28.5% of isolates of *S. epidermidis* had the cMLS~B~ phenotype \[[@B18]\]. However, Gatermann et al. clearly described a lower percentage of isolates of *S. haemolyticus* with the phenotype MS~B~ equal to 30.2% \[[@B19]\]. For the isolates of *S. epidermidis* researched on with the cMLS~B~ and iMLS~B~ phenotypes, the occurrence of the *ermC* gene was demonstrated and with the MS~B~ phenotype, the *msrA* gene. However, 3 out of 5 *S. haemolyticus* isolates with the cMLS~B~ phenotype had the *msrA* gene, but did not have the *emrC* gene. Moreover, in the group of isolates of *S. haemolyticus* with the MS~B~ resistance phenotype, it was demonstrated that one isolate had no *msrA* gene. Probably, those isolates had other genes coding the erythromycin resistance. The recorded lack of *ermA* and *ermB* genes among the isolates researched on is in conformity with the results of other scientists researching CNS who indicated the presence of these genes only as high as 1.8% -- 7.2% for *ermA* and below 1% for *ermB*\[[@B20]\].

The gentamicin resistance was 93% for S*. epidermidis*, 100% for *S. haemolyticus* and it was higher than quoted in the literature for *S. epidermidis* 69.2 -- 89.5% \[[@B17],[@B21]\] and for CNS altogether 85% except the results obtained by Bialkowska-Hobrzanska et al. where for both *S. epidermidis* and S*. haemolyticus* the resistance equaled 100% \[[@B16]\]. In the case of amikacin, the resistant strains of S*. epidermidis* constituted 51% of those studied, whereas 31% of *S. haemolyticus* isolates were amikacin-resistant.

From among the genes coding aminoglycoside resistance, the most frequently identified gene was *aac(6′)/aph(2″)* which both in *S. epidermidis* and S*. haemolyticus* occurred in 90% of cases. In the case of CNS isolates isolated from neonates researched by Klingenberg et al. 69.4% of subjects had the *aac(6′)/aph(2″)* gene \[[@B21]\]. Also, among isolates coming from various groups of patients with hospital infections, the main role in coding aminoglycoside resistance had the *aac(6′)/aph(2″)* gene occurring in 70 -- 90% of CNS isolates \[[@B13]\]. Characteristic of *S. haemolyticus* was the presence, along with the *aac(6′)/aph(2″)* gene, of another gene coding aminoglycoside resistance, meaning *aph(3′)-IIIa* (78%). The comparison of resistance obtained by means of phenotypic methods and genotypic methods enabled observing certain discrepancies. Similarly, Choi et al. observed that only in ca. 50% of CNS isolates there existed a correlation between the phenotype of amikacin resistance and the genotype \[[@B13]\]. According to recommendations of EUCAST (2012) \[[@B10]\], the isolates demonstrating gentamicin resistance are to be treated as having a general aminoglycoside resistance with the exception of streptomycin, as this one is most probably coded by the *aac(6′)/aph(2″)* gene the product of which modifies antibiotics such as gentamicin, kanamycin, tobramycin and amikacin \[[@B22]\]. The phenotype of gentamicin resistance, despite the missing *aac(6′)/aph(2″)* gene, may be caused by the presence of other genes coding aminoglycoside resistance which were not determined in the method used. The observed lack of aminoglycoside resistance phenotype in 3 isolates of *S. epidermidis* having the *aac(6′)/aph(2″)* gene probably signifies the loss of functionality of that gene.

The determination of glycopeptide resistance constitutes a significant part of the characteristics of the CNS isolates as these antibiotics are most frequently administered in the empirical treatment of MRCNS infections in VLBW neonates. In the pool of the studied CNS isolates, all of them were susceptible to vancomycin, which is concurrent with observations made by other researchers dealing with CNS isolated from neonatal infections \[[@B5],[@B6],[@B17]\]. Nevertheless, the MIC value for individual isolates achieved the point of 4 mg/L which is the cut-off point for resistant isolates \[[@B10]\]. The fact of obtaining vancomycin resistance by coagulase-negative staphylococci is confirmed by cases of vancomycin resistance among CNS isolates isolated from infections in various groups of patients, which were recorded by several different research groups \[[@B23]\]. In the case of teicoplanin in the pool of isolates researched, resistance was proven for 13% of *S. epidermidis* and 3% of S*. haemolyticus*, which constitutes a conformation of increasing glycopeptide antibiotic resistance. Similar results were obtained by Trueba et al. where 30.4% of isolates of *S. epidermidis* and 35.7% of *S. haemolyticus* turned out to be teicoplanin-resistant \[[@B24]\] and Kristyof et al. where 32% of *S. haemolyticus* demonstrated resistance \[[@B25]\].

Conclusions
===========

The multi-drug resistance profiles obtained for isolates of coagulase-negative staphylococci isolated from infections of VLBW neonates hospitalized in NICUs indicate that there is a need to constantly monitor the resistance of these strains. At present, the drugs of choice are vancomycin and teicoplanin with the reservation that a quick selection of teicoplanin-resistant isolates of CNS is possible.

Competing interests
===================

The authors declare that they have no competing interests.

Authors' contributions
======================

MBW designed the study, analyzed and interpreted the data, financially supported the study and wrote the manuscript; MBK and EG collected the data about VLBW neonates; MS collected the CNS isolates; MG and ML performed the molecular studies; JWM and PBH designed the Polish Neonatology Surveillance Network (PNSN); MB prepared the literature. All authors read and approved the final manuscript.

Acknowledgements
================

The study was approved by Jagiellonian University Bioethical Committee decision no. KBET/94/B/2009. This study was supported by a grant from the National Science Centre no. N N401 615 340.
